by divibasicbldev | Dec 6, 2022 | Press Releases
PAS-003 is a first in class monoclonal antibody targeting Alpha 5 Beta 1 integrin as a treatment for amyotrophic lateral sclerosis (ALS) and other neuroinflammatory-driven CNS diseasesMIAMI BEACH, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics...
by divibasicbldev | Nov 29, 2022 | Press Releases
MIAMI BEACH, Fla., Nov. 28, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central...
by divibasicbldev | Oct 17, 2022 | Press Releases
Pasithea’s Chairman, Prof. Lawrence Steinman, to be Awarded Honorary Doctorate by University of Buenos AiresMIAMI BEACH, Fla., Oct. 17, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...
by divibasicbldev | Sep 20, 2022 | Press Releases
Mr. Novak brings over 30 years of board and management experience at innovative life sciences companiesMIAMI BEACH, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a...
by divibasicbldev | Sep 15, 2022 | Press Releases
— Dr. Cudkowicz is a pioneer in the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases — MIAMI BEACH, Fla., Sept. 15, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA)...
by divibasicbldev | Sep 9, 2022 | Press Releases
MIAMI BEACH, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric...
